Dechra Pharmaceuticals PLC (LON:DPH – Get Free Report) passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of GBX 3,386.14 ($42.68) and traded as high as GBX 3,813.71 ($48.07). Dechra Pharmaceuticals shares last traded at GBX 3,810 ($48.03), with a volume of 302,148 shares.
Analysts Set New Price Targets
A number of equities analysts have recently commented on DPH shares. Numis Securities restated a “buy” rating and set a GBX 4,000 ($50.42) price objective on shares of Dechra Pharmaceuticals in a research note on Monday, May 22nd. Deutsche Bank Aktiengesellschaft restated an “outperform” rating and set a GBX 4,070 ($51.30) price objective on shares of Dechra Pharmaceuticals in a research note on Thursday, May 25th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, Dechra Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of GBX 3,672 ($46.29).
Dechra Pharmaceuticals Stock Performance
About Dechra Pharmaceuticals
Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies.
- Five stocks we like better than Dechra Pharmaceuticals
- P/E Ratio Calculation: How to Assess Stocks
- 2 Stocks That Doubled EPS Estimates and Flashing Buy Signals
- How to Invest in Energy
- Toyota vs Tesla: The Tortoise And The Hare Race Has A New Meaning
- Trading Halts Explained
- 5 Critical Takeaways From MongoDB’s Q2 Results for AI Investors
Receive News & Ratings for Dechra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dechra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.